LPTX - Leap Tx Accounting Value per Share

Official company branding of Leap Tx (LPTX)

Leap Therapeutics, Inc. (LPTX) maintains high authority within the scientific community, confirming its status as a promising developer of immuno-oncology solutions. This book value per share chart demonstrates steady dynamics, where 0.14 represents the current level of the metric. Financial stability is bolstered by partnerships with industry behemoths to develop DKN-01 and robust patent protection for antibodies, ensuring the long-term value of the company's assets.

LPTX Leap Therapeutics, Inc. Net Asset Value per Share (07/04/2022 - 11/13/2025)

LPTX (Leap Therapeutics Inc): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Quotes Leap Tx|LPTX - Analyst Forecast Prices
- market capitalization statistics:
Market Valuation Leap Therapeutics, Inc.|LPTX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Leap Therapeutics|LPTX - Total Stockholders' Equity|Market Value to Book Value Ratio leaptx.com|LPTX - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Leap Therapeutics, Inc.|LPTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Leap Tx|LPTX - Company Cumulative Debt|Debt to Book Capitalization Ratio Leap Therapeutics, Inc.|LPTX - Company Long-Term Debt|Company Short-Term Debt Leap Therapeutics|Quick Ratio leaptx.com
- earnings and multiples data:
LPTX - Annual Net Income
Basic company analysis:LPTX - leaptx.com
Manufactured products of Leap Tx

Full capacity utilization of Leap Therapeutics, Inc. (LPTX) biopharmaceutical antibody production facilities directly impacts the absolute book value per share, reflecting the efficiency of capital management. This indicator is calculated as the ratio of net assets to the number of shares outstanding, allowing investors to assess the real value of their ownership stake and promptly identify capital dilution or asset write-downs.

Competitor analysis for Leap Therapeutics, Inc.

IBRX: Accounting Value per Share|Immunocore Corp - Book Price of a Share|JANX (Janux Therapeutics) - Accounting Value per Share|Equity per Share RCUS|Net Assets per Single Share Zymeworks|Net Asset Value per Share Tango Therapeutics Inc TNGX|Net Assets per Single Share Iovance (IOVA)|Immatics Biotechnologies - Equity per Share|Book Value per Share XNCR (Xencor, Inc.)|CMPX - Accounting Value per Share|REPL - Net Assets per Single Share|Net Asset Value per Share Lyell|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share Compugen Ltd|Net Asset Value per Share iobiotech.com IOBT|Book Value per Share STRO|MiNK Therapeutics Inc. (INKT) - Book Value of One Share|Werewolf Therapeutics, Inc. - Accounting Value per Share|Immix Biopharma Inc. (IMMX) - Net Asset Value per Share|ALXO: Accounting Value per Share|Accounting Value of a Share CUE (cuebiopharma.com)|PDSB: Book Value per Share|SONN - Net Assets per Share|Net Assets per Single Share MAIA Biotechnology Inc|Accounting Value per Share Liminatus (LIMN)|Net Assets per Single Share LAVA Therapeutics N.V. (LVTX)|Accounting Value per Share nextcure.com NXTC|Intensity Therapeutics, Inc. - Accounting Value per Share|Book Value per Share Sensei Biotherapeutics Inc SNSE|TOVX - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)